Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 17/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | KIF5B | P33176 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17966627 | 1.00 | EGLN1 (0.42) | EGLN1RETTDO2JAK2FLT3 | |
| SCHEMBL30175375 | 1.00 | EGLN1 (0.42) | EGLN1RETTDO2JAK2FLT3 | |
| SCHEMBL18789230 | 1.00 | EGLN1 (0.42) | EGLN1RETTDO2JAK2FLT3 | |
| SCHEMBL17966637 | 1.00 | EGLN1 (0.42) | EGLN1RETTDO2JAK2FLT3 | |
| SCHEMBL30175348 | 1.00 | EGLN1 (0.42) | EGLN1RETTDO2JAK2FLT3 | |
| Hydrochloric Acid SCHEMBL29501567 | 0.98 | EGLN1 (0.41) | EGLN1RETTDO2JAK2FLT3 | |
| Hydrochloric Acid SCHEMBL28604580 | 0.98 | EGLN1 (0.41) | EGLN1RETTDO2JAK2FLT3 | |
| Hydrochloric Acid SCHEMBL18789240 | 0.98 | EGLN1 (0.41) | EGLN1RETTDO2JAK2FLT3 | |
| Hydrochloric Acid SCHEMBL28608786 | 0.98 | EGLN1 (0.41) | EGLN1RETTDO2JAK2FLT3 | |
| Hydrochloric Acid SCHEMBL28430937 | 0.98 | EGLN1 (0.41) | EGLN1RETTDO2JAK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118726295-A | Omega-aminotransferase mutant with high catalytic activity, construction method and application thereof | 中国科学院苏州生物医学工程技术研究所 | 2024-10-01 | — | — | CN | claimed |
| CN-118726295-A | Omega-aminotransferase mutant with high catalytic activity, construction method and application thereof | 中国科学院苏州生物医学工程技术研究所 | 2024-10-01 | — | — | CN | disclosed |
| CN-118620860-A | Omega-aminotransferase mutant and application thereof in asymmetric synthesis of platinib drug intermediate | 中国科学院苏州生物医学工程技术研究所 | 2024-09-10 | — | — | CN | disclosed |
| CN-115605477-B | Pyrazolo [1,5-a ] pyridine derivative, preparation method, composition and application thereof | 深圳众格生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-114181205-B | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118056823-A | Preparation of key intermediate of platinib | 江苏慧聚药业股份有限公司 | 2024-05-21 | — | — | CN | disclosed |
| EP-3371171-B1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-111423416-B | Inhibitors of RET | 缆图药品公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-116023396-A | Nitrogen-containing spiro compound and medical application thereof | 中国医药研究开发中心有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925684-A | Pyrimidine derivative and preparation method and application thereof | 徐诺药业(南京)有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111285875-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115605477-A | Pyrazolo [1,5-a ] pyridine derivative and preparation method, composition and application thereof | 深圳众格生物科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2022053046-A1 | PYRAZOLOPYRIDINE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
| CN-114181205-A | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-111606886-A | Pyrazole derivatives, preparation method thereof and application thereof in medicines | 察略盛医药科技(上海)有限公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-111423416-A | Inhibitors of RET | 蓝图药品公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-111285875-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| CN-108473468-B | Inhibitors of RET | 蓝图药品公司 | 2020-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NCOA4, CCDC47, CCDC6 | EGLN1 3833/4885RET 20/4885TDO2 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.